Navigation Links
Targeted toxin active in platinum-resistant ovarian cancers
Date:4/6/2013

WASHINGTON -- A new antibody-guided drug has shown promising activity in a phase I trial involving ovarian cancer patients with platinum drug-resistant disease, researchers from Dana-Farber Cancer Institute will report today at the annual meeting of the American Association for Cancer Research. The findings (abstract LB-290) will be discussed at a press conference on Saturday, April 06, 2013, 1:00 p.m., ET, in Room 153, in the Washington Convention Center and later at an oral presentation on Tuesday, April 09, 2013, 4:00 p.m. to 4:20 p.m. in room 146, in the Washington Convention Center.

Joyce Liu, MD, MPH, first author of the study, said that among 29 patients who received the antibody-drug conjugate at what was found to be the maximum tolerated dose, there was one complete response and four partial responses. "In addition, there were additional patients with prolonged stable disease who were able to stay on treatment," said Liu, of the gynecologic oncology treatment center at Dana-Farber.

The responses all occurred in patients whose tumors had high expression of the MUC16 protein to which the drug is targeted. Known as DMUC5754A, the drug conjugate consists of an antibody, which recognizes the MUC16 protein expressed by ovarian cancer cells, fused to a toxin, MMAE, which prevents cancer cells from dividing. Targeting the drug conjugate specifically to ovarian cancer cells reduced adverse effects of the toxin on healthy tissues and organs, said Liu. She called the safety profile "encouraging." Most common adverse effects were fatigue, nausea, and vomiting. This phase 1 multicenter trial is the first use in humans of DMUC5754A, and the responses, which Liu called "a nice sign of activity in a very challenging type of ovarian cancer to treat," merit further testing in a phase II trial, which is being planned. "If the activity of this drug is confirmed in additional trials, this will represent a novel type of therapy for ovarian cancer," Liu said.


'/>"/>

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. The future of personalized and targeted cancer therapy
2. Medicaid Fraud in New York Targeted by New House Report
3. Targeted Equine Nutrition Launches New Website For Horse Lovers
4. Banning food ads targeted at kids
5. Study finds tiny, targeted drug particles may be effective in treating chronic diseases
6. Blood Test Plus Targeted Care May Stop Heart Failure Before It Starts
7. Medical Advertising Agency bryantBROWN Healthcare Introduces Targeted Point-of-Care Promotions to Help Law Firms Connect More Directly With Patients and Caregivers
8. Tuberculosis and neglected diseases targeted by new center
9. Lancet Oncology: Long-term side-effects of targeted therapies in pediatric cancer patients
10. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces Quick Weight Loss for Women of All Ages With Targeted Diet Plan
11. High Complexity Laboratory Testing Supports New Targeted Therapies for Leukemias and Lymphomas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... 22, 2015 As interest in the value ... gains momentum worldwide, Rev. Eric J. Hall , president ... (HCCN), will be the keynote speaker on January 27 ... public health system. , The conference, “Hope and Resilience: Innovative ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a list of ... . , Some types of vehicles cannot be covered under ... blog post to see if their vehicle qualifies for auto insurance ... of the cars that cannot be covered by a plan. Clients ...
(Date:1/22/2015)... 2015 Step into a macabre world ... Museum of Virginia. Wicked Plants, the Museum’s latest featured ... 75 poisonous, carnivorous and diabolical plants inside of a ... uncover the biochemical, physical and neurological processes between botanicals ...
(Date:12/26/2014)... The US represents the largest market for CRC ... forecast estimates that sales of branded therapies were $2.23 billion. ... high incidence of the disease, high drug treatment rate, and ... Increased sales of CRC therapies over the forecast period will ...
Breaking Medicine News(10 mins):Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... Laboratories, L.P.,today announced that the U.S. Food and Drug ... vitamin D3 product for the,treatment of mild-to-moderate plaque psoriasis ... a chronic skin disorder that affects 2 to 3 ... red, scaly patches of skin and,caused by an abnormally ...
... To mark American Heart,Month, deCODE genetics (Nasdaq: DCGN ... will offer its deCODEme Cardio Scan(TM), the unique new ... of heart,attack, stroke and atrial fibrillation, intracranial and abdominal ... of,$100. , On Thursday, February ...
... 3 NxStage Medical, Inc. (Nasdaq: NXTM ), ... to release its financial results for the fourth quarter and ... 2009 before the opening of the financial markets.NxStage will also ... Thursday, March 12, 2009 to discuss its fourth quarter and ...
... 3 The Albert and Mary Lasker Foundation ... , the immediate past director of the National Institutes of ... Directors."We are delighted that Dr. Zerhouni has agreed to join ... , President of the Lasker Foundation. "The Lasker Foundation is ...
... to Chief Marketing Officer and PACS Industry Veteran ... ManagerWASHINGTON, Feb. 3 Compressus, Inc., leaders in ... team with the promotion of Janine Broda to ... Shawn Gibbons as vice president and general manager ...
... The Female Health Company (NYSE Alternext: FHC) today ... to discuss its operating results for the first quarter ... Tuesday, February 10, 2009. The Company plans to ... day. Shareholders and other interested parties may participate in ...
Cached Medicine News:Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 2Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 3Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 4Health News:deCODEme(TM) Takes on Heart Disease in February 2Health News:deCODEme(TM) Takes on Heart Disease in February 3Health News:deCODEme(TM) Takes on Heart Disease in February 4Health News:deCODEme(TM) Takes on Heart Disease in February 5Health News:NxStage to Report Fourth Quarter and Full Year 2008 Financial Results 2Health News:Lasker Foundation Welcomes Elias Zerhouni to Board of Directors 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 3Health News:The Female Health Company Schedules First Quarter Conference Call for February 10, 2009 2
(Date:1/23/2015)... Idaho , Jan. 23, 2015  Now available for ... No. 7,849,611) support that prevents ankle sprains by cushioning ... brace, it fits securely around the outside of any ... mobility & comfort while still offering protection against sprains. ...
(Date:1/23/2015)... , Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), ... equipment for all forms of sports, including extreme motor ... brace, announced today that the UISP Lega Motociclismo Lombardia, ... all riders to wear a neck brace during its ...
(Date:1/23/2015)... BOSTON , January 23, 2015 Heptares ... is delighted to announce that the Malcolm Campbell ... Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions to ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... N.J., May 26, 2011 Johnson & Johnson (NYSE: ... its Pharmaceuticals business at a meeting with the investment ... and pharmaceuticals segment will review how the business plans ... needs and outpace pharmaceutical market growth with an optimized ...
... Pharmaceuticals, Inc. (NASDAQ: AMLN ) ("Amylin" or "the ... the Southern District of California issued a temporary restraining order ... ) ("Lilly") relating to its litigation with respect to the ... District Court restrained Lilly from proceeding with its plans to ...
Cached Medicine Technology:Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 2Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 3Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 4Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 5Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly 2Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly 3Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly 4
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
... 10% Povidone Iodine USP, 1% available Iodine, ... prep, Povidone Iodine Gel helps to minimize ... patient, thus reducing the chance of patient ... a one step gel for venipuncture site ...
... Gel is a viscous antimicrobial that contains ... for broad-spectrum germicidal action. As a preoperative ... minimize the pooling of prepping solutions under ... patient burns. Povidone Iodine Topical Gel is ...
... Povidone Iodine Prep Solution is appropriate ... paint, wet soak or spray); disinfecting ... antiseptic treatment of lacerations and abrasions. ... anti-infective agent in hospital and office ...
Medicine Products: